It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
Several candidate COVID-19 vaccines were developed from diverse platforms. One of these was the BBIBP-CorV vaccine (also known as the Sinopharm COVID-19 vaccine) which was made by the Chinese state-owned pharmaceutical business Sinopharm in China and adopted by the United Arab Emirates (UAE) (Zhang et al., 2021). Sinopharm COVID-19 vaccine is an inactivated vaccine that introduces a dead copy of SARS-CoV-2 into the body by a two-dose schedule, with 14 or 21 days between the 2 doses. By inserting the vaccine dose intramuscularly, the dead antigens from the virus are employed to make antibodies that prepare the immune system for future attacks by the virus. (Xia et al., 2021). The traditional inactivated whole-virus vaccines do not lead to clinical disease. In this technology, the inactivated viruses maintain their ability to replicate in vivo with mild or no symptoms (Forni and Mantovani, 2021).
Phases 1 and 2 of the clinical trials for the Sinopharm COVID-19 vaccine were carried out in China over 1 trial for each phase. A total enrollment of 640 participants showed that the vaccine triggered a COVID-19 neutralizing antibody response with a low rate of adverse reactions. The most common side effects were fever and pain at the site of injection and fever; however, these were mild and self-limiting and did not require treatment (Sharma et al., 2020). Phase 3 was carried out over 4 trials in the following countries: the UAE, Bahrain, Egypt, Jordan, Peru and Argentina, with a total 69 000 people enrolled. The UAE approved the vaccine on December 9, 2020; the UAE announced that the vaccine was 86% efficacious, according to the interim results of its phase 3 trial (Xia et al., 2021).
Having administered over 2 million doses of the vaccine as of mid-January 2021, the UAE Ministry of Health reported the vaccine to be 100% effective in preventing mild and severe COVID-19 cases (China to run human coronavirus vaccine trial in UAE 2020, Development of an Inactivated Vaccine Candidate, 2021, Cyranoski, 2020, Zahid et al., 2021). Moreover, the World Health Organization (WHO) announced that most side effects of the Sinopharm COVID-19 vaccine in 3 clinical trials on 16 671 participants aged 18–59 years were mild to moderate, with headache, fatigue, and injection site reactions being the most common (World Health Organization (WHO) 2021).
Published data to support adverse reactions to the Sinopharm COVID-19 vaccine are lacking. Only 2 studies focus on this vaccine (Hatmal et al., 2021, Jayadevan et al., 2021), and fear of the new vaccine is a driver of vaccine hesitancy (Riad et al., 2021).
Knowledge on what happens post-vaccination among the general population is still limited. Describing what to expect after the first and second dose of vaccination will help lower apprehension about this type of vaccine, increase public confidence in vaccine safety, and accelerate the vaccination process against COVID-19 (Hatmal et al., 2021, Jayadevan et al., 2021). The results of this study will be reassuring to those who are fearful of the Sinopharm COVID-19 vaccine. Therefore, the goal of this study was to provide evidence on Sinopharm COVID-19 vaccine side effects after receiving the first and second dose, as approved by the UAE.
The Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV,[1] the Sinopharm COVID-19 vaccine,[2] or BIBP vaccine,[2][3][4] is one of two inactivated virus COVID-19 vaccines developed by Sinopharm's Beijing Institute of Biological Products (sometimes written as Beijing Bio-Institute of Biological Products,[5] resulting in the two different acronyms BBIBP and BIBP for the same vaccine). It completed Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants.[6] BBIBP-CorV shares similar technology with CoronaVac and Covaxin, other inactivated virus vaccines for COVID-19.[7] Its product name is SARS-CoV-2 Vaccine (Vero Cell),[8][9][10] not to be confused with the similar product name of CoronaVac.[11][12] Peer-reviewed results published in JAMA of Phase III trials in United Arab Emirates and Bahrain showed BBIBP-CorV 78.1% effective against symptomatic cases and 100% against severe cases (21 cases in vaccinated group vs. 95 cases in placebo group).[13] In December 2020, the UAE previously announced interim results showing 86% efficacy.[14] While mRNA vaccines like the Pfizer–BioNTech COVID-19 vaccine and Moderna COVID-19 vaccine showed higher efficacy of over 90%, those present distribution challenges for some nations as they require deep-freeze facilities and trucks. BBIBP-CorV could be transported and stored at normal refrigerated temperatures.[15] BBIBP-CorV is being used in vaccination campaigns by certain countries in Asia,[16][17][18] Africa,[19][20][21] South America,[22][23][24] and Europe.[25][26][27] Sinopharm expects to produce one billion doses of BBIBP-CorV in 2021.[28] By May, Sinopharm had supplied 200 million doses.[29]
originally posted by: Zrtst
a reply to: KTemplar
Might I suggest if you are under the age of 40 do not get the JJ. EudraVigilance database has confirmed 26,041 deaths and Slovenia has suspended its use due to a 20 year old succumbed to the jab.
Remember when people said “if it saves just one life, it’s worth it”? What percentage of deaths are we to determine as reasonable?
originally posted by: IndieA
a reply to: 727Sky
Why wouldn't you just be okay with natural immunity?